Welcome!

News Feed Item

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Trigeminal Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Trigeminal Neuralgia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Trigeminal Neuralgia 28
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Merz Pharma GmbH & Co. KgaA 29
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 29
Desitin Arzneimittel GmbH 30
Clinical Trial Overview of Desitin Arzneimittel GmbH 30
Convergence Pharmaceuticals Ltd. 31
Clinical Trial Overview of Convergence Pharmaceuticals Ltd. 31
Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Top Institutes / Government 33
Stanford University 33
Clinical Trial Overview of Stanford University 33
Thomas Jefferson University 34
Clinical Trial Overview of Thomas Jefferson University 34
University Health Network 35
Clinical Trial Overview of University Health Network 35
National Institute of Dental and Craniofacial Research 36
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 36
Shahid Sadoughi University of Medical Sciences and Health Services 37
Clinical Trial Overview of Shahid Sadoughi University of Medical Sciences and Health Services 37
FDA Office of Orphan Products Development 38
Clinical Trial Overview of FDA Office of Orphan Products Development 38
University of Malaya 39
Clinical Trial Overview of University of Malaya 39
Riken Advanced Science Institute 40
Clinical Trial Overview of Riken Advanced Science Institute 40
University College London 41
Clinical Trial Overview of University College London 41
Capital Medical University 42
Clinical Trial Overview of Capital Medical University 42
Five Key Clinical Profiles 43
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 60

List of Tables
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Trigeminal Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Trigeminal Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 29
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Desitin Arzneimittel GmbH, 2014* 30
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Convergence Pharmaceuticals Ltd., 2014* 31
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Allodynic Therapeutics, LLC, 2014* 32
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 33
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 34
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 35
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Dental and Craniofacial Research, 2014* 36
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Sadoughi University of Medical Sciences and Health Services, 2014* 37
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2014* 38
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malaya, 2014* 39
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Riken Advanced Science Institute, 2014* 40
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University College London, 2014* 41
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Capital Medical University, 2014* 42

List of Figures
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 59


Read the full report:
Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Tintri focuses on the Ops side of the DevOps, which basically is pushing more and more of the accessibility of the infrastructure to the developers and trying to get behind the scenes," explained Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
"We focus on composable infrastructure. Composable infrastructure has been named by companies like Gartner as the evolution of the IT infrastructure where everything is now driven by software," explained Bruno Andrade, CEO and Founder of HTBase, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
In this presentation, Striim CTO and founder Steve Wilkes will discuss practical strategies for counteracting fraud and cyberattacks by leveraging real-time streaming analytics. In his session at @ThingsExpo, Steve Wilkes, Founder and Chief Technology Officer at Striim, will provide a detailed look into leveraging streaming data management to correlate events in real time, and identify potential breaches across IoT and non-IoT systems throughout the enterprise. Strategies for processing massive ...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...